ARTICLE

EFFICACY OF ULTRASOUNDGUIDED DOUBLE LUMEN CENTRAL VENOUS CATHETER INSERTION IN MINIMIZING MECHANICAL COMPLICATIONS AND BLOODSTREAM INFECTIONS AN EMPIRICAL EVIDENCE OF PAKISTAN

  1. HOME
  2. ARTICLE

09 Pages : 69-73

http://dx.doi.org/10.31703/gdddr.2023(VIII-II).09      10.31703/gdddr.2023(VIII-II).09      Published : Jun 2023

Efficacy of Ultrasound‐Guided Double Lumen Central Venous Catheter Insertion in Minimizing Mechanical Complications and Bloodstream Infections: An Empirical Evidence of Pakistan

Abstract

    The aim of the study was to compare the outcomes of ultrasound‐guided double‐lumen central venous catheter (DLC) insertion and without ultrasound guidance in reducing mechanical complications and bloodstream infections. This quasi‐experimental study was conducted at Urology Department in collaboration with the Anesthesia department at GMC Teaching Hospital Gujranwala. The study had 60 insertions in each group. The insertion duration ranged from 8‐50 days in Group A and 9‐60 days in the B group. Placements were done at the right internal jugular and right subclavian veins. Four patients in Group A and five patients in Group B experienced catheter‐related bloodstream infections (CRBSI), but the difference was not significant. The Charlson Comorbidity Index (CCI) was 0‐10 in Group A and 0‐8 in Group B. Group A had no mechanical complications, while three patients in Group B experienced manageable complications. In conclusion, ultrasound‐guided DLC placement improves safety but does not reduce CRBSI.

    Dialysis, DLC, Ultrasound

    (1) Khalid Hussain
    Assistant Professor & Head, Department of Urology, GMC /Gujranwala Teaching Hospital, Gujranwala, Punjab, Pakistan.
    (2) Attiq Ur Rehman Khan
    Assistant Professor, Department of Urology, GMC/ Gujranwala Teaching Hospital, Gujranwala, Punjab, Pakistan.
    (3) Salman Athar Qureshi
    Associate Professor, Department of Anesthesia, GMC/ Gujranwala Teaching Hospital, Gujranwala, Punjab, Pakistan.
    (4) Ali Umair Tariq
    Student MBBS, Gujranwala Medical College, Gujranwala, Punjab, Pakistan.
    (5) Maria Tariq
    PGR, Department of Urology, GMC/ Gujranwala Teaching Hospital, Gujranwala, Punjab, Pakistan.
    (6) Bilal Ahmed
    PGR, Department of Urology, GMC/ Gujranwala Teaching Hospital, Gujranwala, Punjab, Pakistan.
Fulltext PDF

References

  • Amsterdam, J. D., & Shults, J. (2009). Does tachyphylaxis occur after repeated antidepressant exposure in patients with Bipolar II major depressive episode? Journal of Affective Disorders, 115(1-2), 234–240. https://doi.org/10.1016/j.jad.2008.07.007
  • Amsterdam, J. D., Williams, D., Michelson, D., Adler, L. A., Dunner, D. L., Nierenberg, A. A., Reimherr, F. W., & Schatzberg, A. F. (2009). Tachyphylaxis after Repeated Antidepressant Drug Exposure in Patients with Recurrent Major Depressive Disorder. Neuropsychobiology, 59(4), 227–233. https://doi.org/10.1159/000226611
  • Buchborn, T., Lyons, T., & Knöpfel, T. (2018). Tolerance and Tachyphylaxis to Head Twitches Induced by the 5-HT2A Agonist 25CN-NBOH in Mice. Frontiers in Pharmacology, 9. https://doi.org/10.3389/fphar.2018.00017
  • Darmani, N. A., & Gerdes, C. F. (1995). Temporal differential adaptation of head-twitch and ear-scratch responses following administration of challenge doses of DOI. Pharmacology Biochemistry and Behavior, 50(4), 545–550. https://doi.org/10.1016/0091-3057(94)00340-8
  • Goto, S., Terao, T., Tomita, M., & Uchimura, N. (2012). Aripiprazole may be free from tachyphylaxis: Preliminary findings. Psychiatry and Clinical Neurosciences, 66(2), 160–162. https://doi.org/10.1111/j.1440-1819.2011.02301.x
  • Kinrys, G., Gold, A. K., Pisano, V. D., Freeman, M. P., Papakostas, G. I., Mischoulon, D., Nierenberg, A. A., & Fava, M. (2019). Tachyphylaxis in major depressive disorder: A review of the current state of research. Journal of Affective Disorders, 245, 488–497. https://doi.org/10.1016/j.jad.2018.10.357
  • Katz, G. (2011). Tachyphylaxis/ tolerance to antidepressive medications: a review. The Israel Journal of Psychiatry and Related Sciences, 48(2), 129–135. https://pubmed.ncbi.nlm.nih.gov/22120449/
  • Lieb, J., & Balter, A. (1984). Antidepressant tachyphylaxis . Medical Hypotheses, 15(3), 279–291. https://doi.org/10.1016/0306-9877(84)90018-5
  • Pietrzykowski, A. Z., & Treistman, S. N. (2008). The Molecular Basis of Tolerance. Alcohol Research & Health, 31(4), 298–309. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3860466/
  • Rothschild, A. J. (2008). The Rothschild Scale for Antidepressant Tachyphylaxis: reliability and validity . Comprehensive Psychiatry, 49(5), 508–513. https://doi.org/10.1016/j.comppsych.2008.03.002
  • Skaff, R. (2019). Tachyphylaxis and desensitization depression . CNS Spectrums, 1–2. https://doi.org/10.1017/s1092852919001445
  • Sjöstedt, P., Enander, J., & Isung, J. (2021). Serotonin Reuptake Inhibitors and the Gut Microbiome: Significance of the Gut Microbiome in Relation to Mechanism of Action, Treatment Response, Side Effects, and Tachyphylaxis. Frontiers in Psychiatry, 12. https://doi.org/10.3389/fpsyt.2021.682868
  • Svensson, C. K. (2022). Attenuation of Response to Repeated Drug Administration: A Proposal for Differentiating Tachyphylaxis and Tolerance. Journal of Pharmacology and Experimental Therapeutics. https://doi.org/10.1124/jpet.121.000978
  • Targum, S. D. (2014). Identification and treatment of antidepressant tachyphylaxis. Innovations in Clinical Neuroscience, 11(3-4), 24–28. https://pubmed.ncbi.nlm.nih.gov/24800130/
  • Uchida, H., & Mamo, D. C. (2009). Dosing of antipsychotics in schizophrenia across the life-spectrum. Progress in Neuro- Psychopharmacology & Biological Psychiatry, 33(6), 917–920. https://doi.org/10.1016/j.pnpbp.2009.04.023

Cite this article

APA

    APA : Hussain, K., Khan, A. U. R., & Qureshi, S. A. (2023). Efficacy of Ultrasound‐Guided Double Lumen Central Venous Catheter Insertion in Minimizing Mechanical Complications and Bloodstream Infections: An Empirical Evidence of Pakistan. Global Drug Design & Development Review, VIII(II), 69-73. https://doi.org/10.31703/gdddr.2023(VIII-II).09

CHICAGO

    CHICAGO : Hussain, Khalid, Attiq Ur Rehman Khan, and Salman Athar Qureshi. 2023. "Efficacy of Ultrasound‐Guided Double Lumen Central Venous Catheter Insertion in Minimizing Mechanical Complications and Bloodstream Infections: An Empirical Evidence of Pakistan." Global Drug Design & Development Review, VIII (II): 69-73 doi: 10.31703/gdddr.2023(VIII-II).09

HARVARD

    HARVARD : HUSSAIN, K., KHAN, A. U. R. & QURESHI, S. A. 2023. Efficacy of Ultrasound‐Guided Double Lumen Central Venous Catheter Insertion in Minimizing Mechanical Complications and Bloodstream Infections: An Empirical Evidence of Pakistan. Global Drug Design & Development Review, VIII, 69-73.

MHRA

    MHRA : Hussain, Khalid, Attiq Ur Rehman Khan, and Salman Athar Qureshi. 2023. "Efficacy of Ultrasound‐Guided Double Lumen Central Venous Catheter Insertion in Minimizing Mechanical Complications and Bloodstream Infections: An Empirical Evidence of Pakistan." Global Drug Design & Development Review, VIII: 69-73

MLA

    MLA : Hussain, Khalid, Attiq Ur Rehman Khan, and Salman Athar Qureshi. "Efficacy of Ultrasound‐Guided Double Lumen Central Venous Catheter Insertion in Minimizing Mechanical Complications and Bloodstream Infections: An Empirical Evidence of Pakistan." Global Drug Design & Development Review, VIII.II (2023): 69-73 Print.

OXFORD

    OXFORD : Hussain, Khalid, Khan, Attiq Ur Rehman, and Qureshi, Salman Athar (2023), "Efficacy of Ultrasound‐Guided Double Lumen Central Venous Catheter Insertion in Minimizing Mechanical Complications and Bloodstream Infections: An Empirical Evidence of Pakistan", Global Drug Design & Development Review, VIII (II), 69-73

TURABIAN

    TURABIAN : Hussain, Khalid, Attiq Ur Rehman Khan, and Salman Athar Qureshi. "Efficacy of Ultrasound‐Guided Double Lumen Central Venous Catheter Insertion in Minimizing Mechanical Complications and Bloodstream Infections: An Empirical Evidence of Pakistan." Global Drug Design & Development Review VIII, no. II (2023): 69-73. https://doi.org/10.31703/gdddr.2023(VIII-II).09